Financiado en parte por Yuhan
Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease
Lee YJ, Lee SJ, Kim JW, Lee SH, Kim GS, Park JH, Cho JM, Kang WC, Yoon HJ, Kim WH, Lee SJ, Lee JB, Jang JY, Shin S, Park IH, Kwon SU, Kim S, Hong SJ, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y, Kim BK, Ez-PAVE Investigators
The New England journal of medicine · 10 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Yuhan
- Universidad u hospital
- Cardiovascular Research Center
Según 2 financiadores declarados.
Publicación
- Publicado
- 2026-03-28 · N Engl J Med · vol. 394 · número 14 · págs. 1365–1375
- Editorial
- Massachusetts Medical Society
- Citado
- 28 citas · más que el 100% de estudios similares · 178.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 33 trabajos
- Acceso
- De pago
- Áreas de investigación
- Lipoproteins and Cardiovascular Health · Antiplatelet Therapy and Cardiovascular Diseases · Acute Myocardial Infarction Research
- Palabras clave
- LDL cholesterol lowering, atherosclerotic cardiovascular disease, secondary prevention, cardiovascular events, statin therapy, creatinine elevation, myocardial infarction, stroke, revascularization, unstable angina
- MeSH
- humans, cardiovascular diseases, disease progression, recurrence, anticholesteremic agents, hydroxymethylglutaryl-coa reductase inhibitors, treatment outcome, drug therapy, combination, hospitalization, cardiovascular surgical procedures, follow-up studies, aged, middle aged, female, male, atherosclerosis, cholesterol, ldl, practice guidelines as topic, secondary prevention, republic of korea, kaplan-meier estimate, ezetimibe
25 autores
- Yong‐Joon Lee🇰🇷Yonsei University; Severance Hospital
- S J Lee🇰🇷Yonsei University; Severance Hospital; Soonchunhyang University Hospital Cheonan
- Jin Won Kim🇰🇷Yonsei University; Severance Hospital; Korea University Guro Hospital
- Sang‐Hyup Lee🇰🇷Yonsei University; Severance Hospital; Soonchunhyang University Hospital Cheonan
- Gwang-Sil Kim🇰🇷Inje University; Inje University Sanggye Paik Hospital
- Jae Hyoung Park🇰🇷Korea University Anam Hospital
- Jin‐Man Cho🇰🇷Kyung Hee University Hospital at Gangdong
- Woong Chol Kang🇰🇷Gachon University Gil Medical Center
- Hyuck‐Jun Yoon🇰🇷Keimyung University Dongsan Hospital; Keimyung University
- Won–Ho Kim🇰🇷Daejeon Eulji Medical Center, Eulji University
- Seung-Jin Lee🇰🇷Yonsei University; Severance Hospital; Soonchunhyang University Hospital Cheonan
- Jin Bae Lee🇰🇷Daegu Catholic University Medical Center
- Ji-Yong Jang🇰🇷National Health Insurance Service Ilsan Hospital
- Sanghoon Shin🇰🇷Ewha Womans University Seoul Hospital
- Ik Hyun Park🇰🇷Samsung Changwon Hospital; Sungkyunkwan University
- Sung Uk Kwon🇰🇷Inje University Ilsan Paik Hospital
- Sunwon Kim🇰🇷Korea University Ansan Hospital
- Sung‐Jin Hong🇰🇷Yonsei University; Severance Hospital
- Chul‐Min Ahn🇰🇷Yonsei University; Severance Hospital
- Jung‐Sun Kim🇰🇷Yonsei University; Severance Hospital; Korea University Guro Hospital
- Young‐Guk Ko🇰🇷Yonsei University; Severance Hospital
- Donghoon Choi🇰🇷Yonsei University; Severance Hospital
- Myeong‐Ki Hong🇰🇷Yonsei University; Severance Hospital
- Yangsoo Jang🇰🇷Yonsei University; Severance Hospital
- Byeong‐Keuk Kim🇰🇷Yonsei University; Severance Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Despite guideline recommendations, evidence from randomized trials evaluating the appropriate low-density lipoprotein (LDL) cholesterol target for secondary prevention in patients with atherosclerotic cardiovascular disease remains limited.
Methods
In this open-label superiority trial conducted in South Korea, we randomly assigned patients with atherosclerotic cardiovascular disease in a 1:1 ratio to a target LDL cholesterol level of less than 55 mg per deciliter (1.4 mmol per liter) (intensive-targeting group) or less than 70 mg per deciliter (1.8 mmol per liter) (conventional-targeting group). The primary end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, any revascularization, or hospitalization for unstable angina at 3 years. Safety was also assessed.
Results
Of 3048 patients who underwent randomization, 1526 were assigned to the intensive-targeting group and 1522 to the conventional-targeting group. The median follow-up was 3.0 years. The median LDL cholesterol level during the trial was 56 mg per deciliter (1.4 mmol per liter) in the intensive-targeting group and 66 mg per deciliter (1.7 mmol per liter) in the conventional-targeting group. A primary end-point event occurred in 100 patients (Kaplan-Meier estimate of cumulative incidence, 6.6%) in the intensive-targeting group and in 147 patients (Kaplan-Meier estimate of cumulative incidence, 9.7%) in the conventional-targeting group (hazard ratio, 0.67; 95% confidence interval, 0.52 to 0.86; P = 0.002). The incidence of prespecified safety end points was similar in the two trial groups, except for a lower incidence of creatinine elevation in the intensive-targeting group.
Conclusions
Among patients with atherosclerotic cardiovascular disease, targeting an LDL cholesterol level of less than 55 mg per deciliter resulted in a lower risk of cardiovascular events at 3 years than targeting a level of less than 70 mg per deciliter. (Funded by the Cardiovascular Research Center and Yuhan; Ez-PAVE ClinicalTrials.gov number, NCT04626973.).
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.